硬骨素
特立帕肽
医学
骨质疏松症
德诺苏马布
骨矿物
骨吸收
内科学
化学
生物化学
Wnt信号通路
基因
作者
Brigitte Uebelhart,Serge Ferrari
出处
期刊:Revue médicale suisse
[La Revue Medicale Suisse]
日期:2021-04-21
卷期号:17 (735): 784-787
摘要
Romosozumab is a monoclonal antibody against sclerostin. Its dual effect on bone is to increase formation and decrease resorption. Sub-cutaneous injections of romosozumab are administered monthly for one year and must be relayed with a bone resorption inhibitor. Romosozumab followed by denosumab is associated with high increase of bone mineral density and decrease of fragility fractures. Gain of bone mineral density and reduction of fragility fractures are more important with romosozumab as compared with alendronate. The increase in bone mineral density is higher with romosozumab as compared to teriparatide in patients previously treated with alendronate. The use of romosozumab (Evenity) is admitted for patients with high risk of fractures but without serious vascular events.
科研通智能强力驱动
Strongly Powered by AbleSci AI